newsfilter
← Latest News
Business Wire·

CEL-SCI Announces Closing of Offering

CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a clinical stage cancer immunotherapy company, today announced the closing of its best-efforts offering of 2,500,000 shares of its common stock. Each share of